The discovery of the BCR-ABL fusion gene on the Philadelphia (Ph) chromosome in 1985 was the start of a new era in understanding the molecular basis of hematologic malignancies. It provided the rationale for producing first imatinib and then a series of small molecules designed to inhibit the tyrosine kinase activity of the Bcr-Abl oncoprotein, all of which can induce complete cytogenetic remissions in the majority of patients with chronic myelogenous leukemia (CML) in the chronic phase. However, we still do not know for sure whether the BCR-ABL fusion gene is really the initiating lesion for the chronic phase of CML and we have an incomplete understanding of the so-called genomic instability that underlies the production of the fusion gene and predisposes the Ph-positive clone to acquire further genetic events that lead to advanced-phase disease. Moreover, it is clear that though some of the mutant Ph-positive subclones that develop in patients taking tyrosine kinase inhibitors (TKIs) are the direct cause of the resistance observed, in other cases, its cause is unclear. It is likely that in the next few years we will see (1) improved methods for predicting responses to TKIs, (2) the use of TKIs in combination with other effective molecules such as farnesyl transferase inhibitors, and (3) a gradual reduction in the proportion of chronic-phase patients resistant to therapy.

Keywords:
BCR-ABL, Chronic myelogenous leukemia, Imatinib, Tyrosine kinase inhibitor
1.
Nowell PC, Hungerford DA: A minute chromosome in human granulocytic leukemia. Science 1960;132:1497.
2.
Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa banding. Nature 1997;243:290–293.
3.
Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G: Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984;36:93–99.
4.
Shtivelman E, Lifshitz B, Gale RP, Canaani E: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550–554.
5.
Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by 210bcr-abl gene of the Philadelphia chromosome. Science 1990;87:6649–6653.
6.
Elefanty AG, Hariharan IK, Cory S: Bcr-Abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 1990;9:1069–1078.
7.
Kelliher MA, McLaughlin J, Witte ON, Rosenberg N: Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 1990;87:6649–6653.
8.
Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, Pendergast AM, Bronson R, Aster JC, Scott ML, Baltimore D: Efficient and rapid induction of a chronic myelogenous leukemia-like disease in mice receiving p210bcr-abl-transformed bone marrow. Blood 1998;92:3780–3792.
9.
Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J: Acute leukaemia in bcr/abl transgenic mice. Nature 1990;344:251–253.
10.
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 1996;2:561–566.
11.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.
12.
Melo JV, Barnes DJ: Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007;7:441–453.
13.
Lukasova E, Kozubek S, Kosubek M, Kjeronská J, Rýznar L, Horáková J, Krahulcová E, Horneck G: Localisation and distance between ABL and BCR genes in interphase nuclei of bone marrow cells of control donors and patients with chronic myeloid leukaemia. Hum Genet 1997;100:525–535.
14.
Neves H, Ramos C, da Sila MG, Parreira A, Parreira L: The nuclear topography of ABL, BCR, PML and RARα genes: evidence for gene proximity in specific phases of the cell cycle and stages of hematopoietic differentiation. Blood 1999;93:1197–1207.
15.
Saglio G, Storlazzi CT, Giugliano E, Surace C, Anelli L, Rege-Cambrin G, Zagaria A, Jimenez Velasco A, Heiniger A, Scaravaglio P, Torres Gomez A, Roman Gomez J, Archidiacono N, Banfi S, Rocchi M: A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: possible involvement in the genesis of Philadelphia chromosome. Proc Natl Acad Sci USA 2002;99:9882–9887.
16.
Ito T, Seyama T, Mizuno T, Hayashi T, Iwamoto KS, Dohi K, Nakamura N, Akiyama M: Induction of BCR-ABL fusion genes by in vitro X-irradiation. Jpn J Cancer Res 1993;84:105–109.
17.
Deininger MW, Bose S, Gora-Tybor J, Yan XH, Goldman JM, Melo JV: Selective induction of leukemia-associated fusion genes by high dose ionizing radiation. Cancer Res 1998;58:421–425.
18.
Spencer A, Granter N: Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation. Exp Hematol 1999;27:1397–1401.
19.
Finch SC: Radiation-induced leukemia: lessons from history. Best Pract Res Clin Haemat 2007;20:109–118.
20.
Fialkow PJ, Gartler SM, Yoshida A: Clonal origin of chronic myelocytic leukemia. Proc Natl Acad Sci USA 1967;58:1468–1471.
21.
Fialkow PJ, Jacobson RJ, Papayannopoulou T: Chronic myelocytic leukemia: clonal origin in a stem cell common to granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977;63:125–130.
22.
Lisker R, Casas L, Mutchinick O, Perez-Chavez F, Labardini J: Late-appearing Philadelphia chromosome in two patients with chronic myelogenous leukemia. Blood 1980;56:812–814.
23.
Kovitz C, Kantarjian H, Garcia-Manero G, Cortes J: Myelodysplastic syndromes and acute leukemia developing after imatinib therapy for chronic myeloid leukemia. Blood 2006;108:2811–2813.
24.
Pawarode A, Sait SNJ, Nganga A, Coignet LJ, Barcos M, Baer MR: Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities. Leuk Res 2007;31:1589–1592.
25.
Fialkow PJ, Martin PJ, Najfeld V, Penfold GK, Jacobson RJ, Hansen JA: Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood 1981;58:158–163.
26.
Raskind WH, Ferraris AM, Najfeld V, Jacobson RJ, Fialkow PJ: Further evidence for the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia. Leukemia 1993;7:1163–1167.
27.
Zaccaria A, Valtenti AM, Donti E, Gozzetti A, Ronconi S, Spedicato F: Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia. Haematologica 2007;92:564–565.
28.
Radich J, Dai HD, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS: Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006;103:2794–2799.
29.
Brazma D, Grace C, Howard J, Melo JV, Holyoke T, Apperley JF, Nacheva EP: Genomic profile of chronic myelogenous leukemia: imbalances associated with disease progression. Genes Chromosomes Cancer 2007;46:1039–1050.
30.
Pendergast AM, Muller AJ, Havlik MH, Clark R, McCormick F, Witte ON: BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 1991;66:161–171.
31.
Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CL, Schlessinger J: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993;75:175–185.
32.
Melo JV, Deininger MWN: Biology of chronic myelogenous leukemia – signaling pathways of initiation and transformation. Hematol Oncol Clin North Am 2004;118:545–568.
33.
Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, Ganser A, Eder M, Scherr M: Expression of miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 2007;109:4399–4405.
34.
Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY, Weinmann R, Holyoake TL: BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008;111:2843–2853.
35.
Apperley JF: Part 1: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018–1029.
36.
Yong ASM, Szydlo RM, Goldman JM, Apperley JF, Melo JV: Molecular profiling of CD34+ cells identifies low expression of CD7 along with high expression of proteinase 3 and elastase as predictors of longer survival in patients with CML. Blood 2006;107:205–212.
37.
Thomas J, Wang L, Clark RE, Pirmohamed M: Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739–3745.
38.
White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, Zannettino A, Lynch K, Manley PW, Hughes T: Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: high doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007;110:4046–4072.
39.
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation of amplification. Science 2001;293:876–880.
40.
Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW: Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003;101:4611–4614.
41.
Khorashad JS, Anand M, Marin D, Apperley JF, Goldman JM, Kaeda JS: The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006;20:939–940.
42.
Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, Stoffregen EP, McWeeney S, Kovacs I, Park B, Druker BJ, Deininger MW: High sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naïve patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005;106:2128–2137.
43.
Jiang X, Saw KM, Eaves A, Eaves C: Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia cells. J Natl Cancer Inst 2007;99:680–693.
44.
de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M: Imatinib for newly diagnosed patients with chronic myeloid leukaemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:1–5.
45.
Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E, Nieborowska-Skorska M, Blasiak J, Skorski T: BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004;104:3746–3753.
46.
Nieborowska-Skorska M, Stoklosa T, Datta M, Czechowska A, Rink L, Slupianek A, Koptyra M, Seferynska I, Krszyna K, Blasiak J, Skorski T: ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle 2006;5:994–1000.
47.
Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, Pierce AJ, Fishel R, Skorski T: BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001;8:795–806.
48.
Gaymes TJ, Mufti GJ, Rassool FV: Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer. Cancer Res 2002;62:2791–2797.
49.
Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M, Blasiak J, Skorski T: BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006;108:319–327.
50.
Penserga ET, Skorski T: Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene 2006;26:11–20.
51.
Eaves CJ, Eaves AC: Progenitor cell dynamics; in Carella AM, Daley GQ, Eaves CJ, Goldman JM, Hehlmann R, Martin Dunitz (eds): Chronic Myeloid Leukemia. Biology and Management. London, Martin Dunitz Publishers, 2001.
52.
Jamieson HM, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL: Granulocyte macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657–667.
53.
Abrahamsson A, Geron I, Gotlib J, Dao KH, Giles F, Newton I, Kavaterchik E, Durocher J, Creusot R, Karimi M, Jones C, Zehnder J, Keating A, Negrin R, Weissman IL, Jamieson CHM: Missplicing of glycogen synthase kinase 3β: a potential mechanism of blast crisis chronic myeloid leukemia stem cell generation (abstract 775). Blood 2007;110:238a.
54.
Janssen JJ, Klaver SM, Pasterkamp G, de Kleijn DP, Schuurhuis GJ, Ossenkoppele GJ: Identification of genes potentially involved in disease transformation of CML. Leukemia 2005;19:998–1004.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.